What Exigent Research does

Exigent Research is a US-based, privately held oncology research network founded through a partnership between the Quality Cancer Care Alliance (QCCA) and the National Cancer Care Alliance (NCCA). The company aggregates 26+ independent community oncology practices operating 185+ sites with 660+ providers serving 426,000+ unique patients annually, primarily as a centralized hub for clinical trial administration rather than as a direct care provider. Its core platform combines three service modules: centralized processes (master clinical trial agreements, regulatory submissions, budget and contract negotiation), access to Phase I-IV clinical trials including Accelerated Trials on Demand (ATOD) for just-in-time trial activation, and a proprietary EMR-agnostic data warehouse with automated feeds including NGS testing for feasibility queries, patient identification, and real-world data analysis.

The business model is two-sided. Independent oncology practices join the network to offload administrative burdens and gain access to cutting-edge trials they could not individually support. Pharmaceutical and biotech trial sponsors pay Exigent to access a national footprint of community oncology sites, accelerating trial activation and patient enrollment through a single central point of contact rather than negotiating site-by-site. Exigent's go-to-market is enterprise sales-led: direct recruitment of practices into the network and direct engagement with sponsors via MCTA structures. Pricing is not publicly disclosed and operates through negotiated master and individual agreements. AI tooling enters the workflow through a strategic partnership with Tempus (Patient Query), applied to patient screening rather than developed in-house.

The company is led by Sibel Blau, MD (President/CEO, affiliated with Northwest Medical Specialties) with leadership drawn from across member practices, reflecting the consortium structure. Operations are headquartered in Tacoma, Washington. No funding rounds, M&A activity, or revenue disclosures were found in the source data, and the company's footprint is currently domestic-only.

Name

Exigent Research

Legal name

Exigent Research

Website

https://exigentnetwork.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Exigent Research is a US-based oncology research network aggregating 26+ independent community oncology practices across 185+ sites to provide centralized clinical trial management services for pharmaceutical and biotech sponsors serving community cancer patients.

Ownership category

akta.pro rank

Product category

Oncology Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industries

Site & Investigator Platforms (Site Payments, Feasibility, Activation) (HLACAOAJ), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Oncology clinical research
• Clinical trial management
• Community oncology network
• Cancer research services
• Clinical trial site network

Headquarters

HQ city

Tacoma

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Trial Management Services: Exigent provides centralized administrative services for clinical trials including regulatory submissions, contract and budget negotiations, and master clinical trial agreements at the network level. Revenue is generated through fees from pharmaceutical/biotech sponsors for facilitating trial activation and management.
2. Trial Sponsorship Revenue: The network enables access to cutting-edge Phase I-IV clinical trials and pragmatic trials. Exigent generates revenue through its relationships with trial sponsors who leverage the network for patient enrollment and site activation.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels2 records

Core offering

Exigent Research operates as a next-generation site network connecting independent community oncology practices across the United States with cancer clinical trials sponsored by pharmaceutical and biotech companies. The organization provides centralized processes, structured trial access, and a proprietary, EMR-agnostic data warehouse with automated data sourcing tools that enable faster trial activation, accelerated enrollment, and near-real-time trial lifecycle updates.

Product overview

Exigent Research operates as a network-based clinical research platform that connects independent community oncology practices to accelerate cancer research. The core offering combines the Exigent Research Network (a consortium of 185+ independent oncology sites serving 426,000+ patients annually) with three integrated service modules: Centralized Processes (administrative support, regulatory submissions, master agreements, budget/contract negotiation), Access to Trials (Phase I-IV trials including Accelerated Trials on Demand™ for just-in-time activation, pragmatic trials, and observational trials), and Proprietary Data Warehouse (EMR-agnostic data tools for patient matching, real-world evidence, and network-wide insights). The platform is formed from a partnership between Quality Cancer Care Alliance (QCCA) and National Cancer Care Alliance (NCCA).

Differentiator

Problem solved

Functional benefit

Products and services

• Exigent Research Site Network
• Proprietary EMR-Agnostic Data Warehouse

Named customers6 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• TempuscoreStrategic or Co-development PartnerExigent Research Network partners with Tempus to leverage their AI-powered patient screening tool Patient Query for clinical trials. This partnership enables accelerated Phase I oncology trial enrollment, with Tempus's AI scanning both structured and unstructured clinical data to identify eligible patients across Exigent's network of community oncology practices.
• Quality Cancer Care Alliance (QCCA)coreStrategic or Co-development PartnerQCCA is a founding partner in the formation of Exigent Research. This partnership established the network-based model for accelerating cancer research by combining QCCA's existing network of oncology practices with the National Cancer Care Alliance.
• National Cancer Care Alliance (NCCA)coreStrategic or Co-development PartnerNCCA is a founding partner in the formation of Exigent Research. This partnership contributed to building the deep networks and experience that power Exigent's unique network-based model for clinical cancer research.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Syapse: Syapse partners with community health systems to integrate oncology real-world data into research and precision medicine workflows; overlapping community-oncology data ambition but with a narrower focus on data vs. Exigent's site operations.

Direct peers

• Sarah Cannon Research Institute: Sarah Cannon is HCA Healthcare's oncology-focused clinical trial site network operating across the U.S. with Phase I units and a national reach; directly comparable to Exigent as a community oncology site network serving pharma sponsors.
• US Oncology Research: US Oncology Research, part of McKesson, runs one of the largest community oncology clinical research programs in the U.S., performing Phase I-IV oncology trials; directly comparable network model targeting the same pharma sponsor segment.
• OneOncology: OneOncology is a national partnership of independent community oncology practices; it coordinates research, value-based care, and operational services for its member sites, closely paralleling Exigent's independent-practice network thesis.
• National Cancer Institute (NCI) Community Oncology Research Program (NCORP): NCORP is a federally funded national network of community-based oncology sites conducting NCI-sponsored trials; comparable in function and structure as a multi-site oncology trial network, though sponsor base is government rather than pharma.

Others

• Tempus AI: Tempus is a stated strategic AI/data partner of Exigent via the Patient Query patient-screening tool; not a direct competitor but a critical enabling technology vendor whose AI capabilities directly power Exigent's trial matching.

Broad incumbents

• Labcorp Drug Development (now Fortrea): Fortrea (post-Labcorp spinoff) runs global clinical development services including oncology site work; broader therapeutic scope but overlapping services in clinical trial operations for sponsors.
• ICON plc: ICON is a global CRO with site management and oncology trial capabilities; comparable in trial-activation and patient-recruitment services but operates at substantially larger scale across multiple therapeutic areas.
• IQVIA Oncology: IQVIA is a global CRO with a large oncology site network and data capabilities serving pharma sponsors; overlaps with Exigent in trial operations but at much greater scale and breadth beyond oncology.
• Flatiron Health: Flatiron (a Roche subsidiary) provides oncology-specific real-world evidence and EHR-to-research data technology used by community oncology practices; adjacent to Exigent's data warehouse play and targets the same pharma RWE buyers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/exigent-research-network

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exigent Research